Business

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading

articleLantheus Holdings, Inc.January 2, 20263/company/lantheus-holdings-inc/news/lantheus-announces-closing-spect-business-sale-shine-technologies-2026-01-02
Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

About this update from Lantheus Holdings, Inc.

[{"type":"text","content":"BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced it has completed the previously announced sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. (collectively, “SHINE”). Under the terms of the agreement, SHINE has acquired Lantheus’ SPECT business, including its diagnostic agents (TechneLite® (Technetium Tc 99m generator), NEUROLITE® (Kit for the Preparation of Technetium Tc 99m Bicisate for Injection), Xenon Xe-133 Gas (Xenon Xe-133 Gas), and Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)), the portion of the North Billerica, Massachusetts campus that manufactures Lantheus’ SPECT products, and the SPECT-related Canadian operations. With the SPECT divestiture finalized, Lantheus will focus on its growing commercial portfolio of innovative PET radiodiagnostics and microbubbles, while also advancing its pipeline of radiopharmaceuticals. AdvisorsSolomon Partners Securities, LLC acted as financial advisor to Lantheus in this transaction, while Foley Hoag LLP and Ropes & Gray LLP acted as legal advisors, and Ernst & Young LLP acted as financial and tax advisor. TechneLite® (Technetium Tc 99m generator) INDICATIONS AND USAGE: The TechneLite® generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits. Sodium Pertechnetate Tc 99m Injection is used IN ADULTS as an agent for: Thyroid ImagingSalivary Gland ImagingUrinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.Nasolacrimal Drainage System Imaging Sodium Pertechnetate Tc 99m Injection is used IN CHILDREN as an agent for: Thyroid ImagingUrinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: None known. IMPORTANT SAFETY INFORMATION: Allergic reactions including anaphylaxis have been reported infrequently following the administration of Sodium Pertechnetate Tc ...

More updates from Lantheus Holdings, Inc.